6533b82afe1ef96bd128b666

RESEARCH PRODUCT

FCγRIIa and FCγRIIIa polymorphisms (SNPs) and cetuximab (C) benefit in the EXPERT-C trial.

Andrew WotherspoonSusana Rosello KeranenClare PeckittJanet ThomasIan ChauGina BrownDavid CunninghamDavid Gonzalez De CastroBengt GlimeliusDiana TaitFrancesco SclafaniSanna Hulkki WilsonJaume CapdevilaRuwaida BegumJacqueline Oates

subject

OncologyCancer Researchmedicine.medical_specialtyCetuximabmedicine.drug_classColorectal cancerbusiness.industrySingle-nucleotide polymorphismBioinformaticsMonoclonal antibodymedicine.diseasedigestive system diseasesOncologyInternal medicinemedicinebusinessmedicine.drug

description

3573 Background: FCγRIIa-H131R and FCγRIIIa-V158F SNPs have been reported to enhance the immune-mediated effects of monoclonal antibodies including cetuximab (C) in metastatic colorectal cancer (CR...

https://doi.org/10.1200/jco.2014.32.15_suppl.3573